Editor's Choice
Academic Journal
Main Category: Tuberculosis
Article Date: 07 Jun 2012 - 13:00 PDT
Patient / Public:
Healthcare Prof:
Drug resistant tuberculosis (TB) in China makes up about 1 in every 10 new cases, according to a report based on data from China's Centers for Disease Control and Prevention and published in NEJM (New England Journal of Medicine). Experts say that more rapid testing of the estimated 9 million infected individuals each year globally is crucial. In China alone, there are at least 1 million new infections annually.
The authors explained that they obtained their data from local and regional surveys in China. A national survey of drug-resistant TB in China was carried out by the researchers in 2007.
Yanlin Zhao, Ph.D., Shaofa Xu, M.D., Lixia Wang, M.S., and team estimated what proportion of Chinese TB cases were drug resistant by cluster-randomized sampling of cases in the national public health system, and resistance testing for the first-line use of the following antibiotics, streptomycin, ethambutol, rifampin, and isoniazid, as well as the second-line medications kanamycin and ofloxacin.
They also used patient-interview data in compiling their estimate.
Below are some highlighted data from their study:
- Out of 3,037 new TB cases, 5.7% had MDR (multidrug-resistant) TB
- Out of 892 previously treated cases, 25.6% had MDR TB.
MDR means the TB is resistant to at least rifampin and ironiazid - Out of all patients with TB, new and old cases, 1 in every 4 was resistant to rifampin, isoniazid, or both
- Out of all patients with TB, 1 in every 10 had the multi-drug resistant type
- About 8% of all MDR TB patients had "extensively drug-resistant TB".
Extensively drug-resistant TB refers to infection that is resistant to at least isoniazid, kanamycin, rifampin, and ofloxacin - There were 110,000 MDR TB incidence cases in 2007
- There were 8,200 extensively drug-resistance TB cases in 2007
- In the majority of cases, extensively drug-resistance TB and MDR TB resulted from primary transmission
- Those with the highest risk of MDR TB were patients who had re ceived their last treatment in a TB hospital
- 43.8% of the 226 patients with MDR B had not completed their last treatment. The majority of them had received treatment in hospital. Even among those who completed their treatment, TB recurred after being treated in the public health system.
"China has a serious epidemic of drug-resistant tuberculosis. MDR tuberculosis is linked to inadequate treatment in both the public health system and the hospital system, especially tuberculosis hospitals; however, primary transmission accounts for most cases."
Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
- Additional
- References
- Citations
Yanlin Zhao, Ph.D., Shaofa Xu, M.D., Lixia Wang, M.S., Daniel P. Chin, M.D., Shengfen Wang, Ph.D., Guanglu Jiang, B.S., Hui Xia, M.S., Yang Zhou, M.S., Qiang Li, M.S., Xichao Ou, M.S., Yu Pang, Ph.D., Yuanyuan Song, B.S., Bing Zhao, B.S., Hongtao Zhang, Ph.D., Guangxue He, B.S., Jing Guo, Ph.D., and Yu Wang, M.D.
N Engl J Med 2012; 366:2161-2170June 7, 2012 Please use one of the following formats to cite this article in your essay, paper or report:
MLA
APA
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'10% Of TB Cases In China Are Drug-Resistant Strains'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
back to top | home | privacy policy
MediLexicon International LtdBexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
Tidak ada komentar:
Posting Komentar